Analysis of the humoral and cellular response after the third COVID-19 vaccination in patients with autoimmune hepatitis.
COVID-19 vaccination
autoimmune hepatitis
immunosuppression
Journal
Liver international : official journal of the International Association for the Study of the Liver
ISSN: 1478-3231
Titre abrégé: Liver Int
Pays: United States
ID NLM: 101160857
Informations de publication
Date de publication:
Feb 2023
Feb 2023
Historique:
revised:
23
06
2022
received:
02
05
2022
accepted:
12
07
2022
pubmed:
16
7
2022
medline:
25
1
2023
entrez:
15
7
2022
Statut:
ppublish
Résumé
To explore the humoral and T-cell response to the third COVID-19 vaccination in autoimmune hepatitis (AIH). Anti-SARS-CoV-2 antibody titers were prospectively determined in 81 AIH patients and 53 healthy age- and sex-matched controls >7 days (median 35) after the first COVID-19 booster vaccination. The spike-specific T-cell response was assessed using an activation-induced marker assay (AIM) in a subset of patients. Median antibody levels were significantly lower in AIH compared to controls (10 908 vs. 25 000 AU/ml, p < .001), especially in AIH patients treated with MMF (N = 14, 4542 AU/ml, p = .004) or steroids (N = 27, 7326 AU/ml, p = .020). Also, 48% of AIH patients had antibody titers below the 10% percentile of the healthy controls (9194 AU/ml, p < .001). AIH patients had a high risk of failing to develop a spike-specific T-cell response (15/34 (44%) vs. 2/16 (12%), p = .05) and showed overall lower frequencies of spike-specific CD4 + T cells (median: 0.074% vs 0.283; p = .01) after the booster vaccination compared to healthy individuals. In 34/81 patients, antibody titers before and after booster vaccination were available. In this subgroup, all patients but especially those without detectable/low antibodies titers (<100 AU/ml) after the second vaccination (N = 11/34) showed a strong, 148-fold increase. A third COVID-19 vaccination efficiently boosts antibody levels and T-cell responses in AIH patients and even seroconversion in patients with the absent immune response after two vaccinations, but to a lower level compared to controls. Therefore, we suggest routinely assessing antibody levels in AIH patients and offering additional booster vaccinations to those with suboptimal responses.
Sections du résumé
BACKGROUND & AIMS
OBJECTIVE
To explore the humoral and T-cell response to the third COVID-19 vaccination in autoimmune hepatitis (AIH).
METHODS
METHODS
Anti-SARS-CoV-2 antibody titers were prospectively determined in 81 AIH patients and 53 healthy age- and sex-matched controls >7 days (median 35) after the first COVID-19 booster vaccination. The spike-specific T-cell response was assessed using an activation-induced marker assay (AIM) in a subset of patients.
RESULTS
RESULTS
Median antibody levels were significantly lower in AIH compared to controls (10 908 vs. 25 000 AU/ml, p < .001), especially in AIH patients treated with MMF (N = 14, 4542 AU/ml, p = .004) or steroids (N = 27, 7326 AU/ml, p = .020). Also, 48% of AIH patients had antibody titers below the 10% percentile of the healthy controls (9194 AU/ml, p < .001). AIH patients had a high risk of failing to develop a spike-specific T-cell response (15/34 (44%) vs. 2/16 (12%), p = .05) and showed overall lower frequencies of spike-specific CD4 + T cells (median: 0.074% vs 0.283; p = .01) after the booster vaccination compared to healthy individuals. In 34/81 patients, antibody titers before and after booster vaccination were available. In this subgroup, all patients but especially those without detectable/low antibodies titers (<100 AU/ml) after the second vaccination (N = 11/34) showed a strong, 148-fold increase.
CONCLUSION
CONCLUSIONS
A third COVID-19 vaccination efficiently boosts antibody levels and T-cell responses in AIH patients and even seroconversion in patients with the absent immune response after two vaccinations, but to a lower level compared to controls. Therefore, we suggest routinely assessing antibody levels in AIH patients and offering additional booster vaccinations to those with suboptimal responses.
Identifiants
pubmed: 35840342
doi: 10.1111/liv.15368
pmc: PMC9349728
doi:
Substances chimiques
COVID-19 Vaccines
0
Antibodies, Viral
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
393-400Informations de copyright
© 2022 The Authors. Liver International published by John Wiley & Sons Ltd.
Références
Lee A, Wong SY, Chai LYA, et al. Efficacy of covid-19 vaccines in immunocompromised patients: systematic review and meta-analysis. BMJ (Clinical research ed). 2022;376:e068632.
Ruether DF, Schaub GM, Duengelhoef PM, et al. SARS-CoV2-specific humoral and T-cell immune response after second vaccination in liver cirrhosis and transplant patients. Clin Gastroenterol Hepatol. 2022;20(1):162-172.e9.
Duengelhoef P, Hartl J, Ruther D, et al. SARS-CoV-2 vaccination response in patients with autoimmune hepatitis and autoimmune cholestatic liver disease. United Eur Gastroenterol J. 2022;10:319-329.
Terziroli Beretta-Piccoli B, Lleo A. Is immunosuppression truly associated with worse outcomes in autoimmune hepatitis patients with COVID-19? Liver Int. 2022;42(2):274-276.
Efe C, Lammert C, Tascilar K, et al. Effects of immunosuppressive drugs on COVID-19 severity in patients with autoimmune hepatitis. Liver Int. 2022;42(3):607-614.
Marjot T, Webb GJ, ASt B, et al. COVID-19 and liver disease: mechanistic and clinical perspectives. Nat Rev Gastroenterol Hepatol. 2021;18(5):348-364.
Hoffmann M, Kruger N, Schulz S, et al. The Omicron variant is highly resistant against antibody-mediated neutralization: implications for control of the COVID-19 pandemic. Cell. 2022;185(3):447-56.e11.
Dejnirattisai W, Huo J, Zhou D, et al. SARS-CoV-2 omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses. Cell. 2022;185(3):467-84.e15.
Planas D, Veyer D, Baidaliuk A, et al. Reduced sensitivity of SARS-CoV-2 variant delta to antibody neutralization. Nature. 2021;596(7871):276-280.
Barda N, Dagan N, Cohen C, et al. Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational study. Lancet (London, England). 2021;398(10316):2093-2100.
Hall VG, Ferreira VH, Ku T, et al. Randomized trial of a third dose of mRNA-1273 vaccine in transplant recipients. N Engl J Med. 2021;385(13):1244-1246.
Aikawa NE, Kupa LdVK, Medeiros-Ribeiro AC, Saad CGS, Yuki EFN, Pasoto SG, et al. Increment of immunogenicity after third dose of a homologous inactivated SARS-CoV-2 vaccine in a large population of patients with autoimmune rheumatic diseases. Ann Rheum Dis 2022:81:1036-1043.
Brehm TT, Ullrich F, Thompson M, Küchen J, Schwinge D, Spier A, et al. Three separate spike antigen exposures by COVID-19 vaccination or SARS-CoV-2 infection elicit strong humoral immune responses in healthcare workers. medRxiv. 2022:2022.03.06.22271718.
Patel EU, Bloch EM, Clarke W, et al. Comparative performance of five commercially available serologic assays to detect antibodies to SARS-CoV-2 and identify individuals with high neutralizing titers. J Clin Microbiol. 2021;59(2):e02257-20.
Riester E, Majchrzak M, Muhlbacher A, et al. Multicentre performance evaluation of the elecsys anti-SARS-CoV-2 immunoassay as an aid in determining previous exposure to SARS-CoV-2. Infect Dis Ther. 2021;10(4):2381-2397.
Perry J, Osman S, Wright J, Richard-Greenblatt M, Buchan SA, Sadarangani M, et al. Does a humoral correlate of protection exist for SARS-CoV-2? a systematic review. medRxiv. 2022:2022.01.21.22269667.
Lohse AW, Kögel M, Meyer zum Büschenfelde KH. Evidence for spontaneous immunosuppression in autoimmune hepatitis. Hepatology. 1995;22(2):381-388.